Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

Fig. 2

Median monthly migraine days during follow-up. The migraine days were documented 2 months before the initial erenumab treatment and 3 months after. The patients showed in all migraine types after first injection a significant reduction of the monthly migraine days (* p < 0.05, ** p > 0.01, *** p < 0.001, **** p < 0.0001)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us